Loading
NASDAQHealthcareBiotechnology
Latest quote
$25.61
+$0.69 · +2.77%
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Latest quote
$25.61
+$0.69 · +2.77%
After-hours
$25.61
$0.00 · 0.00%
Oct 8, 4:20 PM ET
Regular session · ET · Market data may be delayed.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Day range
Current $25.61
52-week range
Current $25.61
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
42
Fair Value
Sentiment
65
Bullish
Risk
38
Moderate Risk
Momentum
89
Strong Up
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Day range
Current $25.61
52-week range
Current $25.61
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 551K USD | 571K USD | 1.81M USD | 685K USD |
| Gross profit | — | −551K USD | −571K USD | −1.81M USD | −685K USD |
| Research and development | 10.96M USD | 18.63M USD | 18.3M USD | 29.58M USD | 21.66M USD |
| Selling, general, and administrative | 11.33M USD | 12.49M USD | 18.77M USD | 17.73M USD | 15.14M USD |
| Operating expenses | 22.29M USD | 31.11M USD | 36.49M USD | 47.31M USD | 36.8M USD |
| Interest income | 1.24M USD | 2.55M USD | 3.62M USD | 1.78M USD | 800K USD |
| Interest expense | 32K USD | 90K USD | 144K USD | 219K USD | 670K USD |
| Depreciation and amortization | 139K USD | 1.32M USD | 1.35M USD | 1.35M USD | 685K USD |
| Operating income | −22.29M USD | −31.66M USD | −37.06M USD | −49.12M USD | −37.48M USD |
| Net income | −21.09M USD | −30.16M USD | −34.1M USD | −48.59M USD | −36.79M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$58.50
128.43% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 17, 2025 | 1:20 | — | — |
Effective Jun 17, 2025
1:20
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI5.49M0.05%10.08B USD0.35%$149.29-0.63%
Schwab U.S. Small-Cap ETFSCHA2.55M0.01%21.7B USD0.03%$32.66+0.15%
iShares Micro-Cap ETFIWC1.92M0.15%1.33B USD0.60%$182.79-0.31%
iShares Core S&P Total U.S. Stock Market ETFITOT731.3K0.00%98.16B USD0.03%$168.58-0.41%
Vanguard Extended Market ETFVXF331.47K0.00%95.4B USD0.05%$233.13-0.15%
Schwab U.S. Broad Market ETFSCHB309.75K0.00%45.25B USD0.03%$29.73-0.40%
Direxion Daily S&P Biotech Bull 3X SharesLABU249.75K0.04%597.12M USD0.96%$223-2.09%
Fidelity Nasdaq Composite Index ETFONEQ226.95K—10.94B USD0.21%$107.13-1.22%State Street SPDR S&P Biotech ETFXBISchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCiShares Core S&P Total U.S. Stock Market ETFITOTVanguard Extended Market ETFVXFSchwab U.S. Broad Market ETFSCHBDirexion Daily S&P Biotech Bull 3X SharesLABUFidelity Nasdaq Composite Index ETFONEQAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
